Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsSTU:MYD +1.00%57 Cash Ratio is 0.88 as of Jun. 2026, which is 16% below its 10-year median of 1.05. GuruFocus rates STU:MYD with a GF Score™ of 57/100 and a GF Value™ of €9.98 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 52.88% on this metric.
Myriad Genetics has a Cash Ratio of 0.88. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Myriad Genetics's Cash Ratio or its related term are showing as below:
STU:MYD'
s Cash Ratio Range Over the Past 10 Years
Min: 0.37 Med: 1.05 Max: 1.96
Current: 0.88
During the past 13 years, Myriad Genetics's highest Cash Ratio was 1.96. The lowest was 0.37. And the median was 1.05.
STU:MYD's Cash Ratio is ranked worse than 52.88% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.02
vs STU:MYD: 0.88
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Myriad Genetics Cash Ratio Related Terms
Myriad Genetics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Myriad Genetics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Cash Ratio of 0.88 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Myriad Genetics and its competitors. This is 16% below median its historical median of 1.05. Over the past decade, Myriad Genetics' Cash Ratio has ranged from 0.37 to 1.96. According to the industry distribution chart, Myriad Genetics ranks #110 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 52.9%.
Is Myriad Genetics' Cash Ratio too high?
Myriad Genetics' current Cash Ratio of 0.88 is 16% below median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 1.96. The Medical Diagnostics & Research industry median Cash Ratio is 1.02. Myriad Genetics' value of 0.88 is 13.7% below this industry median. Based on the distribution chart, Myriad Genetics ranks #110 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Cash Ratio compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #110 out of 208 companies for Cash Ratio. This places Myriad Genetics in the lower half of its industry. The industry median Cash Ratio is 1.02. Myriad Genetics' value of 0.88 is 13.7% below this benchmark. Historically, Myriad Genetics' own Cash Ratio has ranged from 0.37 to 1.96 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 1.02, Myriad Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 1.02, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Cash Ratio of 0.88 is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Cash Ratio is 0.88, which is 16% below median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.98, compared to a current price of €2.73 — trading 72.6% below its estimated fair value. The current Cash Ratio is 0.88, which is 16% below median its 10-year median of 1.05 and 13.7% below the Medical Diagnostics & Research industry median of 1.02. Myriad Genetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Cash Ratio is 0.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.73 is trading 72.6% below its estimated GF Value™ of €9.98.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Cash Ratio: 0.88 (16% below median its 10-year median of 1.05)
GF Value™: €9.98 vs. price of €2.73 (72.6% below fair value)
Industry Position: 13.7% below the Medical Diagnostics & Research median (#110 of 208)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
57GF Score
Get the complete analysis for STU:MYD
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
